Intellia Therapeutics price target raised to $35 from $29 at Leerink

Leerink raised the firm’s price target on Intellia Therapeutics (NTLA) to $35 from $29 and keeps an Outperform rating on the shares. Following the company’s topline HAELO results and conference call, the firm is increasing its lonvo-z probability of success to 90% from 75% to reflect clean efficacy/safety and rolling BLA initiation. The stock’s reaction has been somewhat muted as investors balance lonvo-z derisking vs bear arguments on the balance sheet and catalyst vacuum. Intellia will present detailed data at the 2026 European Academy of Allergy and Clinical Immunology Congress, including swimmer plots, subgroup analyses and longer follow-up data-the latter of which Leerink expects to support further differentiation of lonvo-z from chronically dosed options.